About NALCN channel auxiliary factor 1
NALCN channel auxiliary factor 1 (NALF1) is a protein
from Homo sapiens identified by UniProt accession
B1AL88, 458 residues long.
MolForge cross-references it against 0 known binders and
107 disease associations.
Target properties
| Protein name | NALCN channel auxiliary factor 1 |
| UniProt accession | B1AL88 |
| Gene | NALF1 |
| Organism | Homo sapiens |
| Length | 458 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (107)
Diseases linked to this target (Open Targets).
- diverticular disease · score 0.45
- diverticulitis · score 0.42
- mathematical ability · score 0.41
- body mass index · score 0.38
- protein measurement · score 0.33
- sphingomyelin measurement · score 0.32
- daytime rest measurement · score 0.31
- body height · score 0.31
- neurofibrillary tangles measurement · score 0.30
- adolescent idiopathic scoliosis · score 0.30
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-B1AL88-F1 | alphafold | PREDICTED | 61.21 | — |
Amino-acid sequence (458 residues)
MTRGAWMCRQ YDDGLKIWLA APRENEKPFI DSERAQKWRL SLASLLFFTV LLSDHLWFCA EAKLTRARDK EHQQQQRQQQ QQQQQQRQRQ QQQQQRRQQE PSWPALLASM GESSPAAQAH RLLSASSSPT LPPSPGDGGG GGGKGNRGKD DRGKALFLGN SAKPVWRLET CYPQGASSGQ CFTVENADAV CARNWSRGAA GGDGQEVRSK HPTPLWNLSD FYLSFCNSYT LWELFSGLSS PNTLNCSLDV VLKEGGEMTT CRQCVEAYQD YDHHAQEKYE EFESVLHKYL QSEEYSVKSC PEDCKIVYKA WLCSQYFEVT QFNCRKTIPC KQYCLEVQTR CPFILPDNDE VIYGGLSSFI CTGLYETFLT NDEPECCDVR REEKSNNPSK GTVEKSGSCH RTSLTVSSAT RLCNSRLKLC VLVLILLHTV LTASAAQNTA GLSFGGINTL EENSTNEE
Explore NALCN channel auxiliary factor 1 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets